N9289

NVP-231

≥98% (HPLC)

• 동의어(들): N-[2-(benzoylamino)-6-benzothiazolyl]-Tricyclo[3.3.1.13,7]decane-1-carboxamide, adamantane-1-carboxylic acid (2-benzoylamino-benzothiazol-6-yl)amide
• 실험식(Hill 표기법): C₂₅H₂₅N₃O₂S
• CAS Number: 362003-83-6
• Molecular Weight: 431.55
• MDL number: MFCD01988824
• UNSPSC 코드: 12352200
• PubChem Substance ID: 329818618
• NACRES: NA.77

속성

• Quality Level: 100
• 분석: ≥98% (HPLC)
• 양식: powder
• 색상: white to off-white
• solubility: DMSO: >10 mg/mL
• 주관자: Novartis
• 저장 온도: 2-8°C
• SMILES string: O=C(Nc1nc2ccc(NC(=O)C34C[C@H]5C[C@H](C[C@H](C5)C3)C4)cc2s1)c6ccccc6
• InChI: 1S/C25H25N3O2S/c29-22(18-4-2-1-3-5-18)28-24-27-20-7-6-19(11-21(20)31-24)26-23(30)25-12-15-8-16(13-25)10-17(9-15)14-25/h1-7,11,15-17H,8-10,12-14H2,(H,26,30)(H,27,28,29)/t15-,16+,17-,25-
• InChI key: MVSSJPGNLQPWSW-CIRRPZLZSA-N

설명

생화학적/생리학적 작용

Ceramide kinase presents an attractive target for drug development because of its involvement in cell growth and inflammation.

Ceramide kinase presents an attractive target for drug development because of its involvement in cell growth and inflammation. CerK biology is still poorly understood thus discovery and availability of inhibitors will facilitate research at this area. NVP-231 is a newly discovered potent, specific and reversible CerK inhibitor that competitively inhibits binding of ceraminde to CerK.

특징 및 장점

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

안전성 정보

• Storage Class Code: 11 - Combustible Solids
• WGK: nwg
• Flash Point (°F): Not applicable
• Flash Point (°C): Not applicable